TARGETED THERAPEUTIC DELIVERY: SUCCESS THROUGH MAGNETIC MICROCARRIERS by Singh, Arun Kumar et al.
Singh et al                             Journal of Drug Delivery & Therapeutics; 2011, 1(1): 17-23                                             17       
© 2011, JDDT. All Rights Reserved                                                                                                                                                                        
 
Available online at http://jddtonline.info 
REVIEW ARTICLE 
TARGETED THERAPEUTIC DELIVERY: SUCCESS THROUGH MAGNETIC MICROCARRIERS 
*Singh AK1, Danodia A2, Garg SK3 
 
1Devsthali Vidyapeeth College of Pharmacy, Lalpur, Kiccha Road, Rudrapur, Uttarakhand, INDIA-263148 
2Dept of Chemistry, University of Delhi, INDIA- 110007 
3 National Institute of Pharmaceutical Education & Research (NIPER) Hajipur (Bihar), INDIA-844101 
*Corresponding Author’s Email-arunsinghpharma@gmail.com 
  
 Received 10 Oct 2011; Revised 19 Oct 2011; Accepted 20 Oct 2011, Available online 26 Oct 2011 
 
INTRODUCTION 
One of the great challenges in drug therapy is the selective 
delivery (i.e., therapeutic targeting or targeted therapeutic 
delivery) of therapeutics to the intended target. An 
effective delivery system should be defined for a given 
therapeutics according to its physicochemical and 
pharmacokinetic characteristics, to its target site of action, 
and to the pathology to be addressed. 
In recent years, polymeric controlled drug delivery systems 
have evolved as one of the most interesting area in drug 
delivery and drug targeting1-3. The drug release is 
controlled by the properties of the polymer-drug systems 
and to some extent environmental factors such as pH, 
enzymes and inter-patient variance. Despite several 
advantages offered by controlled drug release, a major 
problem associated with all these systems so far developed 
give release rates that are either constant or decrease with 
time, but not augmented delivery on demand4.  
Various nonmagnetic micro carries (nanoparticles, 
microspheres and microparticles etc.) are successfully 
utilized for drug targeting but they show poor site 
specificity and are rapidly cleared off by RES (reticulo 
endothelial system) under normal circumstances. 
Magnetism plays an important role in such cases. 
Magnetically targeted drug delivery system (MT-DDS) 
will be a promising way, which involves binding a drug to 
a small biocompatible magnetically active component, 
entrapped in the biodegradable polymeric matrix and 
formulating in to a pharmacologically active stable 
formulation, which is injected into the blood stream and 
using a high-gradient magnetic field to pull them out of 
suspension in the target region5. Magnetic microspheres 
will be formulated with an intension to produce a depot 
near the target tissue/organ, by placing a suitable magnet 
near it. From the depot, drug will be released slowly & 
carried to the target organ through blood. By localizing the 
drug carrier near the target organ, unwanted distribution of 
drug to non target organ can be avoided. This approach 
will localize the drug only at target site & minimize the 
drug-induced toxicity6-9. Magnetism plays an important 
role in different applications of healthcare; magnetically 
active component is composed of magnetite, which is well 
tolerated by the body. Magnetite (Fe3O4) is a common 
magnetic iron oxide, and it has a cubic inverse spinal 
structure with oxygen forming a FCC closed packing and 
Fe cations occupying the interstitial tetrahedral sites and 
octahedral sites10-11. The electrons can hop between Fe2+ 
and Fe3+ ions in the octahedral sites at room temperature, 
rendering magnetite an important part of half-metallic 
materials. The important characteristics of magnetic 
microspheres for medical applications are nontoxicity, bio-
compatibility, injectability and high level accumulation in 
the target organ. 
MAGNETIC MICROSPHERES:  
Magnetic microspheres are supramolecular particles that 
are small enough to circulate through capillaries without 
producing embolic occlusion (<4 ìm) but are sufficiently 
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susceptible (ferromagnetic) to be captured in micro-vessels 
and dragged in to the adjacent tissues by magnetic fields of 
0.5-0.8 tesla12. Magnetic microspheres are prepared by 
mainly two methods namely phase separation emulsion 
polymerization (PSEP) and continuous solvent evaporation 
(CSE) by using mixture of water soluble drugs (for 
lipophilic drugs, along with the dispersing agent) and 10 
nm magnetite (Fe
3
O
4
) particles in an aqueous solvent of 
matrix material, which are about 1.0 μm in size, that is 
small enough to allow them to be injected intravenously 
without any occlusion in the micro vascular. These 
microspheres are nontoxic and nonreactive with blood 
components. They can be stabilized by heating or 
chemically cross linking albumin to achieve a wide 
spectrum of drug release kinetics. These are infused into an 
artery supplying a given target site. A magnet of sufficient 
field strength is then placed externally over the target area 
to localize the microspheres at the capillary bed in this 
region. In order to localize microspheres in a fast-moving 
arterial system, generally greater field strength is required.  
Magnetic microspheres were prepared by mainly two 
methods: 
1. Phase separation emulsion polymerization (PSEP) 
and 
2. Continuous solvent evaporation (CSE). 
Phase separation emulsion polymerization  
Polymer encapsulated microspheres are synthesized based 
on a modified Phase separation emulsion polymerization 
technique. Briefly aqueous solution of polymer, drug and 
magnetite should be added to the vegetable oil and 
emulsified using a magnetic stirrer at 1,500 rpm for 2 
minutes. The resultant should be stabilized by heating at 
the temperature (100-150 °C). Then cross linking agent 
should be injected drop wise into the resultant emulsion 
under continuous stirring. The magnetic microspheres will 
be formed in the Oil suspension and then should be 
separated from oil by washing procedures. The product 
should be Freeze dried & stored at 4°C.  
Continuous solvent evaporation  
Polymer encapsulated microspheres are synthesized on the 
basis of a Continuous solvent evaporation technique. A 
solution of polymer, drug and magnetite should be added 
to the volatile organic solvent, which forms Auxiliary 
solution on stirring. Resulting solution should be 
homogenized at stirring temperature (22-30
o
C). The 
magnetic microspheres will be formed in the suspension 
and should be separated by centrifugation. The product 
should be Freeze dried & stored at 4°C. The amount and 
rate of drug delivery via magnetic responsive microspheres 
can be regulated by varying size of microspheres, drug 
content , magnetite content , hydration state and drug 
release characteristic of carrier. The amount of drug and 
magnetite content of microspheres needs to be delicately 
balanced in order to design an efficient therapeutic system. 
Magnetic microspheres are characterized for different 
attributes such as particle size analysis includes size 
distribution, surface topography, and texture etc using 
scanning electron microscopy (SEM), drug entrapment 
efficiency, percent magnetite content, and in vitro 
magnetic responsiveness and drug release. 
Desirable characteristics of magnetic microspheres as a 
targeted therapeutic delivery system:  
 The particles should be small enough to remain in 
circulation after injection.  
 The magnetic material should be nontoxic.  
 The polymer should be biocompatible i.e., nontoxic 
and non-immunogenic.  
 It must be able to cross the anatomic barriers.  
 It must be recognized only by the target cells.  
 It must not release the drug before reaching the target.  
 It must release the drug inside the target cells. 
Table 1: Advantages and disadvantages of magnetic microspheres 
ADVANTAGES DISADVANTAGES 
Magnetic microspheres are site specific and by localization of these 
microspheres in the target area, the problem of their rapid clearance by RES is 
also surmounted.  
By the use of magnetic microspheres in the delivery 
system, the drug cannot be targeted to deep seated organs 
in the body.  
Linear blood velocity in capillaries is 300 times less as compared to arteries, 
so much smaller magnetic field is sufficient to retain them in the capillary 
network of the target area.  
Magnetic targeting is an expensive technical approach 
and requires specialized manufacturer and quality 
controlled system.  
Avoidance of acute toxicity directed against endothelium and normal 
parenchyma cell, controlled release within target tissue for intervals of 30 
minutes to 30 hrs. As desired, adaptable to any part of body.  
It needs specialized magnet for targeting, advanced 
technique for monitoring, and trained personnel to 
perform the procedure  
In case of tumour targeting, microsphere can internalize by tumour cells due 
to its much increased phagocytic activity as compared to normal cells.  
Rapid clearance of targeted systems especially antibody 
targeted carriers.  
Problem of drug resistance due to inability of drugs to be transported across 
the cell membrane can be surmounted.  
Drug- antibody inactivation during conjugation.  
Microspheres can transit in to extravascular space thereby creating an 
extravascular drug depot for sustained release of drug within the targeted area.  
Target tissue heterogeneity is the problem 
Adaptable to any part of the body.  Problems of insufficient localizations of targeted systems 
into tumor cells  
Magnetic carrier technology appears to be a significant alternative for the 
biomolecule malformations (i.e. composition, inactivation or deformation).  
Magnetic targeting is an expensive technical approach, 
requires specialized manufacture & QC system 
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TARGETING BY MAGNETIC MICROSPHERES 
Targeting by magnetic microspheres i.e. incorporation of 
magnetic particles in to therapeutic carriers (polymers) and 
using an externally applied magnetic field is one way to 
physically direct this magnetic drug carriers to a desired site, 
Widder first reported on the use of magnetic albumin 
microspheres13. Widder also showed that in the presence of a 
suitable magnetic field, the microspheres are internalized by 
the endothelial cells of target tissues in healthy as well as 
tumor bearing animals14. Gupta and Hung suggested that in 
presence of magnetic field, the microspheres demonstrated 16 
fold increases in the maximum drug concentration, 6 fold 
increases in drug exposure and 6 fold increases in the drug 
targeting efficiency to rat tail target segments15. Morimoto 
and Natsume studied the utilization of magnetic 
microparticulate system for cancer therapy by formulating a 
novel cationic delivery system based on magnetic 
aminodextran microspheres (MADM) and compared with the 
neutral magnetic dextran microspheres (MDM) 16. The 
magnetic microspheres were effectively used for drug 
targeting to tumor cells, cell separation, diagnosis of disease 
and magnetic targeting of radioactivity. 
 
 
Figure 1: Mechanism of magnetic drug targeting 
PRINCIPLE OF TARGETING BY MAGNETIC 
MICROSPHERES 
Magnetic microspheres are a promising method of delivering 
therapeutics to a target site. Very high concentrations of 
therapeutic agents can be achieved near the target site, such as 
a tumor, without any toxic effects to normal surrounding 
tissue or to the whole body. Depending on the type of drug, it 
is then slowly released from the magnetic carriers (e.g. 
release of chemotherapeutic drugs from magnetic micro- 
spheres) or confers a local effect (e.g. irradiation from 
radioactive microspheres; hyperthermia with magnetic 
nanoparticles). It is thus possible to replace large amounts of 
freely circulating drug with much lower amounts of drug 
targeted magnetically to localized disease sites, reaching 
effective and up to several-fold increased localized drug 
levels17-19. 
Magnetic c carriers receive their magnetic responsiveness to a 
magnetic field from incorporated materials such as magnetite, 
iron, nickel, cobalt, neodymium–iron–boron or samarium–
cobalt. Magnetic carriers are normally grouped according to 
size. At the lowe end, we have the ferrofluids, which are 
colloidal iron oxide solutions. Encapsulated magnetite 
particles in the range of 10–500 nm are usually called 
magnetic nanospheres and any magnetic particles of just 
below 1–100_m are magnetic microspheres. In general, 
magnetic liposomes are also included when speaking about 
magnetic carriers. The “shell” material determines the 
reaction of the body to the microsphere. Matrix materials that 
have been tested for the magnetic microspheres include 
chitosan, dextran, poly(lactic acid), starch, poly(vinyl 
alcohol), polyalkylcyanoacrylate, polyethylene imine, carbon, 
polysaccharides, gelatin and proteins20. 
FACTORS INFLUENCING MAGNETIZED 
THERAPEUTIC DELIVERY USING 
MICROSPHERES
21
 
The amount and rate of drug delivery via magnetically 
responsive microspheres can be regulated by varying size of 
microspheres, drug content, magnetite content, their hydration 
state and drug release characteristic of carrier. Actually all 
these factors are interconnected. The size of microspheres is 
related to their drug content by a direct proportionality. 
However, drug content is also governed by the solubility 
characteristic of the drug and method of preparation of 
microspheres. Hydration step of microspheres affect their 
body distribution and drug release rate from the microspheres. 
The magnetic content and magnitude of applied field governs 
the retention of microspheres at targeted sites. In case of 
microspheres with higher magnetic content, smaller magnetic 
field is sufficient for efficient retention of microspheres in the 
targeted area. But by incorporating excessive magnetite into 
the microspheres, the effective space available for the drug in 
microspheres is reduced appreciably. So amount of drug and 
magnetite content of microspheres needs to be delicately 
balanced in order to design an efficient therapeutic system. 
The average particle size was found to increase with 
increasing initiator concentration. It also increased with 
decreasing stabilizer concentration and MPEO 
concentration. Other factors such as the solvent system, the 
particle's porosity, its density, surface coating and aggregation 
tendencies can further influence its overall magnetic 
responsiveness. Drugs Generally Used for Magnetized 
Targeting are Adriyamycin, Doxorubicin, 5Flurouracil, 
Oxantrazole, Cisplatin, Hydrocortisone, Dactinomycin, 
Diclofenac sodium22 Dexamethasone23 etc 
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MAGNET DESIGN 
24, 25
 
The force exerted by a gradient magnetic field is an important 
parameter that governs magnetic targeting of micro carriers. 
The relationship of magnetic force to field gradient and 
magnetic moment of particles is expressed by following 
equation: -  
F=M∇H 
Where,  
F= Force on particles  
M=Magnetic moment of particles after saturation 
magnetization  
∇H= Magnetic field gradient  
This equation explains that spheres with increased magnetic 
moments will experience force sufficient for extra vascular 
migration of proportionately lower field gradients. The 
magnetic moments of microspheres can be increased in three 
ways: -  
 By clustering magnetite at the center of each sphere to 
produce large macro domains.  
 By magnetizing the spheres to saturation levels prior to 
vascular targeting.  
 By substituting one of the newer ferromagnetic 
materials that has high susceptibility than Fe
3
O
4
.  
APPLICATION OF MAGNETIC MICROSPHERES 
1.1 Tumor targeting by clogging of capillaries 
It is also possible to use only the mechanical-physical 
properties of magnetic particles or ferrofluids for therapy. 
One example is the embolization (clogging) of capillaries 
under the influence of a magnetic field26. In this way, tumors 
could be specifically starved of their blood supply.  
1.2 Magnetic targeted delivery of chemotherapeutic agents 
The first clinical cancer therapy trial using magnetic 
microspheres (MMS) was performed by Lübbe et al. in 
Germany for the treatment of advanced solid cancer in 14 
patients. Their MMS were small, about 100 nm in diameter, 
and filled with 4_-epidoxorubicin. The phase I study clearly 
showed the low toxicity of the method and the accumulation 
of the MMS in the target area. However, MRI measurements 
indicated that more than 50% of the MMS had ended up in 
the liver. This was likely due to the particles’ small size and 
low magnetic susceptibility which limited the ability to hold 
them at the target organ. Current preclinical research is 
investigating the use of magnetic particles loaded with 
different chemotherapeutic drugs such as mitomycin C, 
etoposide, paclitaxel or oxaliplatin27. 
Saravanan et al were studied the targeting efficiency and the 
therapeutic efficacy of microspheres in rabbits. The 
microspheres showed drug loading of 9.1, 18.7, 24.9% w/w, 
magnetite content of 27.8-28.9% w/w with an average size 
range of 25-30.6 mum, depending upon the drug-polymer 
ratio. The microspheres effectively reduced joint swelling, but 
lesser extent than the oral diclofenac sodium in high dose, in 
antigen induced arthritic rabbits without producing gastric 
ulceration which was observed in rabbits treated with oral 
diclofenac sodium28. 
The multiple tissue disposition of adriamycin hydrochloride 
delivered via magnetic albumin microspheres, in absence 
(control) and presence of magnetic field (experimental), has 
been investigated in rats by Gupta et al. The results 
quantitatively suggest that the efficacy of magnetic albumin 
microspheres in the targeted delivery of incorporated 
therapeutic agent is predominantly due to the magnetic 
effects, and not alone due to the characteristics of the micro-
carrier system29. 
1.3Retinal therapy by mechanical-physical properties of 
magnetic particles 
Another elegant example is the use of magnetic fluids to 
prevent retinal detachment, thus preventing the patients from 
going blind30. A magnetized sclera buckle, similar to a rubber 
band, is placed around the eye. The magnetic fluid is then 
injected into the eye and immediately drawn towards the 
buckle by its magnetic forces. The mechanical forces push the 
retina back into its original place. 
1.4 Magnetic targeting of radioactive agent 
Magnetic targeting can also be used to deliver therapeutic 
radioisotopes31. The advantage of this method over external 
beam therapy is that the dose can be increased, resulting in 
improved tumor cell eradication, without harm to nearby 
normal tissue. 
Different radioisotopes can treat different treatment ranges 
depending on the radioisotope used the emitters 90Y for 
example will irradiate up to a range of 12mm in tissue. Unlike 
chemotherapeutic drugs, the radioactivity is not released, but 
rather the entire radioactive microsphere is delivered to and 
held at the target site to irradiate the area within the specific 
treatment range of the isotope. Once they are not radioactive 
anymore, biodegradation of the microspheres occurs (and is 
desired). 
Initial experiments in mice showed that intraperitoneally 
injected radioactive poly (lactic acid) based MMS could be 
concentrated near a subcutaneous tumor in the belly area, 
above which a small magnet had been attached18. The dose-
dependent irradiation from the _-emitter 90Y-containing 
MMS resulted in the complete disappearance of more than 
half of the tumors. Magnetic targeted carriers (MTC; from 
FeRx), which are more magnetically responsive iron carbon 
particles, have been radiolabeled in the last couple of years 
with isotopes such as 188Re31, 90Y, 111In and 125I and are 
currently undergoing animal trials28. 
1.5. Magnetic control of pharmacokinetic parameters and 
drug release 
Langer et al. embedded magnetite or iron beads into a drug-
filled polymer matrix and then showed that they could 
activate or increase the release of the drug from the polymer 
by moving a magnet over it or by applying an oscillating 
magnetic field32, 33. The micro-movement within the polymer 
seemed to have shaken the matrix or produced “micro-
cracks,” and thus made the influx of liquid, dissolution and 
efflux of the drug possible. In this way, it was possible to 
magnetically activate the release of insulin from a depot 
underneath the skin34. Done repeatedly, this would allow for 
pulsatile drug delivery. 
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Another mechanistic approach based on magnetic attraction is 
the slowing-down of oral drugs in the gastrointestinal system. 
This is possible by filling an additional magnetic component 
into capsules or tablets. The speed of travel through the 
stomach and intestines can then be slowed down at specific 
positions by an external magnet, thus changing the timing 
and/or extent of drug absorption in stomach or intestines. 
Slowing down the passage of magnetic liposomes with a 
magnet actually increased the blood levels of a drug35. 
1.6 Treatment of tumors with magnetically induced 
hyperthermia 
It is based on the fact that tumor cells are more sensitive to 
temperature than normal cells. In hyperthermia it is essential 
to establish a heat delivery system, such that the tumor cells 
are heated up or inactivated while the surrounding tissues 
(normal) are unaffected.  
Developments by Jordan and Chan led to the current 
hyperthermia application of single domain, dextran-coated 
magnetite nanoparticles in tumors36, 37. The first clinical trial 
is ongoing in Germany38. 
Magnetic hyperthermia is also possible with larger magnetic 
particles, as shown by the group of39. Their 32-_m plastic 
particles contain maghemite and embolize the arterial blood 
supply of the tumor, in addition to the magnetic hyperthermia 
treatment. In an animal study with 10 rabbits, the tumor 
volumes decreased by 50–94% within 2 weeks. 
Ongoing investigations in magnetic hyperthermia are focused 
on the development of magnetic particlesthat are able to self-
regulate the temperature they reach. The ideal temperature for 
hyperthermia is 43– 45 ◦C, and particles with a Curie 
temperature in this range have been described by Kuznetsov 
et al40. 
2. Magnetic systems for the diagnosis of diseases 
The most important diagnostic application of magnetic 
nanospheres is as contrast agents for magnetic resonance 
imaging (MRI). Saini et al. tested 0.5–1 _m sized ferrites in 
vivo for the first time41. Since then, smaller 
superparamagnetic iron oxides (SPIOs) have been developed 
into unimodular nanometer sizes and have since 1994 been 
approved and used for the imaging of liver metastases 
(ferumoxide based Feridex I.V., or Endorem in Europe) or to 
distinguish loops of the bowel from other abdominal 
structures (GastroMark, or Lumirem in Europe). 
3. Separation of subcellular components: 
The era of using magnetic particles with surface markers 
against cell receptors started in 1978 with a seminal paper by 
Kronick et al42. Currently, many different kits for the sample 
preparation, extraction, enrichment and analysis of entire cells 
based on surface receptors, and subcellular/molecular 
components such as proteins, mRNA, DNA are available43. 
Analytical procedures, such as many different immunoassays, 
are often based on magnetic separation44. 
4. Magnetic separation and isolation of DNA  
The conventional protocol for extracting DNA involves cell 
lysis followed by removal of contaminating cellular 
components such as proteins, lipids and carbohydrates; and 
finally isolating DNA using a series of precipitation and 
centrifugation steps, which are difficult to automate. 
Improvement in methods for isolating DNA has been made 
and more recently, methods that rely on the use of solid phase 
have been proposed. One of these kits involves isolation of 
DNA using silica coated magnetic particles [45]. A high 
throughput genome isolation protocol has been developed, 
which is based on SPRI (Solid Phase Reversible 
Immobilization) chemistry [46, 47]. The SPRI protocol is 
based on DNA binding to the surface of carboxyl coated 
paramagnetic particles under the condition of high salt and 
PEG.  
5. Magnetic separation and isolation of poly (A) mRNA 
Biomagnetic separation of mRNA is based on specific 
complementary hybridization between poly A sequence of 
isolated mRNA and oligo (dT)25 sequence covalently linked 
to the surface of paramagnetic particles. In this method oligo 
(dT) 25 coated magnetic beads are added to crude cell or 
tissue lysate. During incubation poly (A) mRNA from the 
lysate are caught onto the surface of oligo (dT)25 coated 
magnetic beads. The beads/mRNA complex is then washed 
magnetically. The mRNA thus isolated is either eluted or 
directly applied for many downstream applications which 
include cDNA library construction, Substractive 
hybridization, Northern hybridization, RT-PCR and in 
vitro translation [48]. 
6. Magnetic separation and isolation of nucleic acid 
binding biomolecules 
Several kits are available in the market that works on the 
principle of magnetic labeling and direct isolation of 
biotinylated molecules such as DNA, RNA or proteins onto 
streptavidin coated magnetic beads (μMACS streptavidin 
Microbeads from Miltenyi Biotec, Germany). These 
biotinylated molecules can then be used for indirect isolation 
of non-biotinylated target molecules that may interact with 
them [49]. The procedure involves complex formation 
between the biotinylated probe (DNA, RNA or proteins) and 
the target molecule (i.e. interacting biomolecules DNA, RNA 
or protein). Based on the interaction of biotin-streptavidin, the 
probe-target complex is then separated from rest of the 
component by addition of streptavidin coated magnetic beads. 
The complex is magnetically isolated and washed to remove 
non-specifically bound molecules. The non-biotinylated 
target molecules can be either eluted off from the complex 
with high purity, whereas the magnetically labeled 
biotinylated probe remains bound to the column. 
7. Applications in Proteomics 
Magnetic particles are now increasingly used as carriers for 
binding proteins, enzymes and drugs. Studies have shown that 
proteins and enzymes can be bound covalently to naked 
magnetic particles in the presence of carbodiimide [50]. Such 
immobilization procedures for proteins, enzymes or drugs 
will have a major impact in various areas of medicine and 
biotechnology. The immobilized biomolecules can be used 
directly for a bioassay or as affinity ligands to capture or 
modify target molecules or cells. On this basis, Ni-NTA 
(nitriloacetic acid) tagged magnetic agarose beads have been 
used for versatile magnetocapture assays using 6xHis-tagged 
proteins [51. The procedure involves use of metal chelating 
nitriloacetic acid (NTA) groups covalently bound to the 
surface of agarose beads, which contain strong magnetic 
particles. The beads are precharged with nickel, which is 
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ready to capture 6xHis-tagged proteins for sensitive 
interaction assays or microscale purification of 6xHis tagged 
proteins.  
8. Immunomagnetic assays 
Magnetic particles have been applied increasingly for various 
immunoassays that include fluoroimmunoassays, enzyme 
immunoassays or radioimmunoassays. Magnetic particles 
bound with primary or secondary antibodies are used for 
separation and quantification of antigens. Use of magnetically 
bound antibodies eliminates the centrifugation step thus 
reducing assay time and simplifying operation thereby 
increasing the efficiency and accuracy of the assay. 
Matsunaga and co-workers [52] have developed a novel 
fluoroimmunoassay method, where a fluorescein 
isothiocyanate (FITC) conjugated monoclonal anti-
Escherichia coli antibody was immobilized onto bacterial 
magnetic particles (BMPs) for detection and removal of E. 
coli. The same group has also developed a 
chemiluminescence enzyme immunoassay with BMPs using 
IgG as a model antigen [53]. Likewise a magnetic bead based 
ELISA has been developed for detection of Staphylococcus 
species [54]. 
9. Drug discovery and genomics applications 
But innovations in newer technologies for genomics and 
proteomics are changing the face of drug discovery. 
Automation has become essential in allowing researchers to 
meet the high through demands of today's research 
environment. The main thrust area where magnetic separation 
is applied in drug discovery is sample preparation that 
includes high throughput genome isolation for sequencing or 
PCR amplification to carry out genotyping, SNP scoring or 
expression profiling.  
C CONCLUSION 
Literature survey is concluded that magnetic microspheres are 
extremely useful carrier system as a target therapeutic 
delivery system. Magnetic microspheres have been 
investigated for targeting drug delivery in chemotherapy due 
to their better tumor targeting, therapeutic efficacy, lower 
toxicity and flexibility, bioseparation magnetic resonance 
imaging, radioactivity, hyperthermia, diagnosis and in 
immunoassay. Magnetic drug delivery by particulate carriers 
is a very efficient method of delivering a drug to localized 
disease site. Very high concentrations of chemotherapeutic or 
radiological agents can be achieved near the target site, such 
as tumour, without any toxic effects to normal surrounding 
tissue or to whole body. IIt might be possible in near future 
that magnetic particles would be used as detection probes for 
a variety of assays, replacing labeling techniques such as 
fluorescence, chemiluminescence and radioactivity. Recently 
magnetic microspheres also used in proteomics and 
genomics. In future, further study by researchers will be 
developed a novel and efficient magnetic microspheres that 
become a promising delivery system for targeting of 
therapeutics. 
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